Although Not Improving DFS, Adjuvant Avelumab May Potentially Reduce the Risk of Death in Patients with High-Risk TNBC By Ogkologos - September 9, 2025 671 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the A-BRAVE study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Cancer in My Community: Continuing to Improve Australia’s Strong Cancer Survival... December 8, 2020 CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated... August 14, 2025 Helping Kids with Cancer Speak for the Supportive Care They Need December 13, 2024 People with Cancer Say Access to Their Clinical Notes Is Valuable November 18, 2020 Load more HOT NEWS Talazoparib Plus Enzalutamide Improves rPFS Over Placebo Plus Enzalutamide in First-Line... EMA Recommends Granting a Conditional Marketing Authorisation for Idecabtagene Vicleucel News digest – naked mole-rats, junk food deals, ovarian cancer drug... Girl’s New College Dorm Has Perfect View Of The Hospital Room...
